The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, presents data from the Phase I dose escalation portion of a study (NCT06158854) investigating the BCMAxCD3 bispecific antibody etentamig in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis. Prof. Sanchorawala notes that the results with this agent are highly encouraging thus far, with deep and rapid hematologic responses being observed. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
